

OVERVIEW

PRESS RELEASES

EVENTS & PRESENTATIONS

CORPORATE GOVERNANCE

MANAGEMENT

BOARD OF DIRECTORS

COMMITTEE COMPOSITION

CONTACT THE BOARD

FINANCIAL INFORMATION

SEC FILINGS

ANNUAL REPORTS

QUARTERLY RESULTS

STOCK INFORMATION

HISTORIC STOCK LOOKUP

INVESTMENT CALCULATOR

ANALYST COVERAGE

INVESTOR FAQs

CONTACT US

EMAIL ALERTS



## INVESTOR RELATIONS

### Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

## STOCK QUOTE


**Price**      **Change**      **High**

Nov 20, 2018 1:31 PM EST

[VIEW DETAILS](#)

Copyright West LLC. Minimum 15 minutes delayed.

## STOCK CHART



## PRESS RELEASES

November 07, 2018 [Melinta Therapeutics Reports Third Quarter 2018 Financial Results](#)

October 31, 2018 [Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors](#)

October 29, 2018 [Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® \(delafloxacin\) for Treatment of CABP](#)

## EVENTS & PRESENTATIONS

[FILTER](#)

[RESET](#)

Nov 07, 2018

[Melinta Therapeutics Q3 2018 Earnings Call](#)

[CLICK HERE FOR WEBCAST](#)

Oct 02,

2018

Melinta Therapeutics, Inc. at the Ladenburg Thalmann  
2018 Healthcare Conference

[CLICK HERE FOR WEBCAST](#)

Oct 01,  
2018

Melinta Therapeutics, Inc. at the 2018 Cantor Fitzgerald  
Global Healthcare Conference

[CLICK HERE FOR WEBCAST](#)



梵

倭

穴